Published on 28 Sep 2022 on Zacks via Yahoo Finance
9 Meters (NMTR) Up on Results From Bowel Syndrome Candidate
9 Meters Biopharma NMTR was up 31.7% pre-market on Sep 27, after the company announced top-line results from its phase II study of its lead candidate, vurolenatide. The candidate is being developed for adults with short bowel syndrome (SBS). The company also reported a successful end-of-phase II meeting with the FDA to progress the candidate to a phase III study. This also impacted the surge in 9 Meters’ stock price.
However, shares of 9 Meters have plunged 78.8% year-to-date compared with the industry’s fall of 28.1%.
